Metastatic Castration Resistant Prostate Cancer Clinical Trial
Official title:
Phase 1/2a Open-label Trial to Evaluate the Safety, Tolerability, PK, PD, Immunogenicity, and Antitumor Activity of LAVA-1207, a PSMA-targeting Bispecific γδ-T Cell Engager, in Patients With Therapy Refractory mCRPC
This is a phase 1/2a, first-in-human study to evaluate the safety and tolerability of LAVA-1207 in patients with therapy refractory metastatic castration resistant prostate cancer
This trial is an open-label Phase 1 and 2a dose escalation trial with an expansion cohort to investigate the safety and tolerability of LAVA-1207 in patients with therapy refractory mCRPC. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02495974 -
European Observational Study of Enzalutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
|
||
| Completed |
NCT03641560 -
A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy
|
Phase 4 | |
| Terminated |
NCT02441517 -
A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel Treatment
|
Phase 4 | |
| Active, not recruiting |
NCT03454750 -
Radiometabolic Therapy (RMT) With 177Lu PSMA 617 in Advanced Castration Resistant Prostate Cancer (CRPC)
|
Phase 2 | |
| Completed |
NCT03776968 -
A Study Evaluating HC-1119 Single-Dose Pharmacokinetics and Effect of Food on Its Pharmacokinetics
|
Phase 1 | |
| Completed |
NCT02471469 -
Personalizing Enzalutamide Therapy by Understanding the Relation Between Tumor mRNAs, miRNAs and Treatment Response
|
||
| Terminated |
NCT03177187 -
Combination Study of AZD5069 and Enzalutamide.
|
Phase 1/Phase 2 | |
| Terminated |
NCT03531827 -
Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment
|
Phase 2 | |
| Active, not recruiting |
NCT02566772 -
Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer
|
Phase 1 | |
| Completed |
NCT03829436 -
TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
|
Phase 1 | |
| Terminated |
NCT05241613 -
A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT02975934 -
A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
|
Phase 3 | |
| Active, not recruiting |
NCT04869488 -
A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
| Completed |
NCT00428220 -
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
|
N/A | |
| Completed |
NCT04056754 -
Study of Abiraterone Acetate in Subjects With Metastatic Castration Resistant Prostate Cancer
|
Phase 3 | |
| Completed |
NCT03658447 -
PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr)
|
Phase 1/Phase 2 | |
| Terminated |
NCT03042312 -
Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapy
|
Phase 2 | |
| Completed |
NCT02991911 -
A Phase 1/1b Study of MEDI3726 in Adults Subjects With Metastatic Castration Resistant Prostate Cancer
|
Phase 1 | |
| Completed |
NCT02426333 -
Optimizing Abiraterone Therapy
|
||
| Completed |
NCT02655822 -
Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers
|
Phase 1 |